Nanocapsules Market Size, Share & Industry Analysis, By Polymer Type (Natural, Synthetic), By Application (Pharmaceutical , Cosmeceuticals, Others (Food Science, Agriculture, and Genetic Engineering)), By Route of Administration (Parenteral Route, Oral Route, Topical Route) And Regional Forecast, 2024-2032

Nanocapsule is a vascular system which  comprises of inner cavity filled with liquid, solid, or semisolid drugs jacketed  with a non-toxic polymeric shell. There is a gradual rise in demand for nanocapusles, owing to the advantages such as targeted delivery, sustained release, and improving aqueous solubility, improvement of drug bioavilability, and improved patient compliance.

Moreover, increase in the commercialisation and R&D in the fields associated with nanocapsules is expected to boost the market growth during the forecast period. For instance, in April 2019, researchers from University of Jyväskylä and Aalto University in Finland developd a customised DNA nanocapsule for the drug delivery.

The nanocapsules market is expected to register a significant growth during the forecast period due to factors such as rising number of chronic diseases worldwide which is fueling the demand for targeted drug delivery. This along with rise in technologically advancements and modernization in the healthcare techniques is anticipated to drive the market growth. However, stringent regulatory framework, high cost and complex process of manufacturing are the major factors anticipated to restrict the growth of nanocapsules market.

Market Segmentation:

Globally, the nanocapsules market can be segmented on the basis of the polymer type, by application, by route of administration, and by region. Based on the polymer type, the market can be segmented into natural and synthetic. Based on application, the market can be segmented into pharmaceuticals, cosmeceuticals, and others. Based on the route of administration, the market can be segmented into parenteral, oral and topical. Geographically, the nanocapsules market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the nanocapsules market are NanoSphere Health Sciences Inc., BioDelivery Sciences International, Inc., Nano Green Sciences Inc., PlasmaChem GmbH, Cerulean Pharma Inc., ANP Technologies, Inc., Jazz Pharmaceuticals, Inc., and other prominent players.

Key Insights:

• Prevalence of Chronic Diseases, By Key Countries/Key Regions


• Key Industry Trends


• New Product Launches


• Key Industry Developments Mergers, Acquisitions, And Collaborations

Regional Analysis:

Geographically, the nanocapsules market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is projected to account for lion’s share of the market. The dominance is due to rising chronic diseases and growing patient awareness & compliance regarding the targeted drug delivery. Europe is anticipated to hold second largest market share in global market. For instance, The Horizon 2020 programme by European Union has allocated about 2 Billion Euros for research and development projects in the field of nanotechnology. Increasing research and development activities with funding from government and private is likely to spur the market growth in this region.

On the other hand, Asia Pacific is expected to register the highest CAGR. Rising number of pharmaceutical industries and increasing healthcare expenditure is likely to propel the market growth of this region. The market in Latin America and the Middle East & Africa are in growing stage. However, growing patient awareness regarding the chronic diseases and the treatment options, these developing regions are likely to help witness a considerable growth in the market in the upcoming years.

Segmentation

Nanocapsules Market Industry Developments

• In September 2020, Sol-Gel announced that FDA has approved its New Drug Application (NDA) filling for Epsolay a topical cream for the treatment of inflammatory lesions of rosacea.


• In August 2017, Jazz Pharmaceutical, Inc. received FDA approval for liposomal encapsulated combination of daunorubicin and cytarabine (Vyxeos) for treatment of adults with newly diagnosed AML.